The in vitro development of extended-release solid oral dosage forms.
A system is described for developing extended-release products, based upon predicting or simulating the entire plasma level-time curve to be expected from the administration of a controlled-release oral dosage form. Termed "biorelevant dissolution," it employs the product's in vitro dissolution behavior and the drug's pharmacokinetic parameters in conjunction with a classical pharmacokinetic model. The basic system is described along with some pertinent examples.
D000284:Administration, Oral; D003692:Delayed-Action Preparations / Q000592:standards*; D004304:Dosage Forms; D012995:Solubility; D013607:Tablets / Q000592:standards; D013678:Technology, Pharmaceutical / Q000295:instrumentation
D003692:Delayed-Action Preparations; D004304:Dosage Forms; D013607:Tablets